Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Fiona Forrestal"'
Autor:
Anita H. Clayton, Robert Lasser, Sagar V. Parikh, Dan V. Iosifescu, JungAh Jung, Mona Kotecha, Fiona Forrestal, Jeffrey Jonas, Stephen J. Kanes, James Doherty
Publikováno v:
American Journal of Psychiatry.
Autor:
Guanfang Wang, Samantha Budd Haeberlein, Spyros Chalkias, Kimberly Umans, Karen Smirnakis, Frederik Barkhof, Derk D. Purcell, Patrick Burkett, Joyce Suhy, Jerome Barakos, Stephen Salloway, Priya Singhal, Fiona Forrestal, Ying Tian
Publikováno v:
JAMA Neurology, 79(1), 13-21. American Medical Association
Salloway, S, Chalkias, S, Barkhof, F, Burkett, P, Barakos, J, Purcell, D, Suhy, J, Forrestal, F, Tian, Y, Umans, K, Wang, G, Singhal, P, Budd Haeberlein, S & Smirnakis, K 2022, ' Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease ', JAMA Neurology, vol. 79, no. 1, pp. 13-21 . https://doi.org/10.1001/jamaneurol.2021.4161
JAMA Neurology
Salloway, S, Chalkias, S, Barkhof, F, Burkett, P, Barakos, J, Purcell, D, Suhy, J, Forrestal, F, Tian, Y, Umans, K, Wang, G, Singhal, P, Budd Haeberlein, S & Smirnakis, K 2022, ' Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease ', JAMA Neurology, vol. 79, no. 1, pp. 13-21 . https://doi.org/10.1001/jamaneurol.2021.4161
JAMA Neurology
Key Points Question What are the characteristics of amyloid-related imaging abnormalities (ARIA) during aducanumab treatment in individuals with early Alzheimer disease? Findings In an integrated safety data set of 2 phase 3 clinical trials (EMERGE a
Autor:
Fiona Forrestal, Howard Fillit, Peter Pemberton-Ross, William Herring, Ian Gopal Gould, Peter Lindgren, Robin Thompson
Publikováno v:
Neurology and Therapy
Introduction Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US Food and Drug Administration to reduce a
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:395-404
Vixotrigine is a voltage and use dependent sodium channel blocker currently under development for treatment of various neuropathic pain indications. The objective of this work was to develop a population pharmacokinetic model and assess effects of va
Autor:
Bassem Maximos, Kristina Deligiannidis, Samantha Meltzer-Brody, E. Quinn Peeper, Robert Lasser, Amy Bullock, Mona Kotecha, null Sigui li, Fiona Forrestal, Manny Garcia, Bridgette Leclair, Jim Doherty
Publikováno v:
American Journal of Obstetrics and Gynecology. 228:S272
Autor:
Sharon Cohen, Ping He, Mihaela Levitchi Benea, Ryan Miller, Fiona Forrestal, Menglan Pang, Carmen Castrillo‐Viguera, John E Harrison, Judy Jaeger, Catherine J. Mummery, Anton P. Porsteinsson, Jeffrey L. Cummings, Ying Tian, Lili Yang, Samantha Budd Haeberlein
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdová, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, Emmanuel Bartholomé, Marie D'Hooghe, Massimo Pandolfo, Bart Van Wijmeersch, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, Mark Freedman, François Grand'Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah Morrow, Michael Yeung, Michal Dufek, Petr Kanovsky, Ivana Stetkarova, Marika Talabova, Jette Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Laura Airas, Irina Elovaara, Juha-Pekka Eralinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun Frenay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, Maria Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wieslaw Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kaminska, Gabriela Klodowska-Duda, Maciej Maciejowski, Ewa Motta, Ryszard Podemski, Andrzej Potemkowski, Teresa Rog, Krzysztof Selmaj, Zbigniew Stelmasiak, Adam Stepien, Andrzej Tutaj, Jacek Zaborski, Alexey Boyko, Zanna Chefranova, Evgeny Evdoshenko, Farit Khabirov, Stella Sivertseva, Eduard Yakupov, Jose Carlos Alvarez Cermeño, Antonio Escartin, Oscar Fernandez Fernandez, Antonio Garcia-Merino, Miguel Angel Hernandez Perez, Guillermo Izquierdo Ayuso, José Meca Lallana, Xavier Montalban Gairin, Celia Oreja-Guevara, Albert Saiz Hinarejos, Martin Gunnarsson, Jan Lycke, Claes Martin, Fredrik Piehl, Homayoun Roshanisefat, Peter Sundstrom, Martin Duddy, Bruno Gran, Timothy Harrower, Jeremy Hobart, Martin Lee, Paul Mattison, Richard Nicholas, Owen Pearson, Waqar Rashid, David Rog, Basil Sharrack, Eli Silber, Ben Turner, Anna Williams, John Woolmore, Carolyn Young, Daniel Bandari, Joseph Berger, Ann Camac, Stanley Cohan, Jill Conway, Keith Edwards, Michelle Fabian, Jack Florin, Steven Freedman, Dennis Garwacki, Myla Goldman, Daniel Harrison, Craig Herrman, Deren Huang, Adil Javed, Stephen Kamin, George Katsamakis, Bhupendra Khatri, Annette Langer-Gould, Sharon Lynch, David Mattson, Tamara Miller, Augusto Miravalle, Harold Moses, Suraj Muley, James Napier, Allen Nielsen, Andrew Pachner, Gabriel Pardo, MaryAnn Picone, Derrick Robertson, Walter Royal, Christopher Sheppard, Ben Thrower, Cary Twyman, Emmanuelle Waubant, Jeanette Wendt, Vijayshree Yadav, Rana Zabad, Greg Zarelli
Publikováno v:
The Lancet Neurology
The Lancet Neurology, 2018, 17 (5), pp.405-415. ⟨10.1016/S1474-4422(18)30069-3⟩
Petersen, T & ASCEND investigators 2018, ' Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension ', Lancet Neurology, vol. 17, no. 5, pp. 405-415 . https://doi.org/10.1016/S1474-4422(18)30069-3
The Lancet Neurology, 2018, 17 (5), pp.405-415. ⟨10.1016/S1474-4422(18)30069-3⟩
Petersen, T & ASCEND investigators 2018, ' Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension ', Lancet Neurology, vol. 17, no. 5, pp. 405-415 . https://doi.org/10.1016/S1474-4422(18)30069-3
BACKGROUND: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc95b87ac32870a3b8f8710dac67e04
https://doi.org/10.1016/s1474-4422(18)30069-3
https://doi.org/10.1016/s1474-4422(18)30069-3
Autor:
Petra Duda, Gabriel Pardo, Howard Rossman, Fiona Forrestal, Michael Kaufman, Marianne T. Sweetser
Publikováno v:
Journal of the Neurological Sciences. 341:22-27
Natalizumab is an immunomodulatory drug approved for the treatment of multiple sclerosis. This randomized, multicenter, open-label study evaluated natalizumab's effects on immunization responses to a recall antigen (tetanus toxoid [TT]) and a neoanti
Autor:
Leonid Gorelik, Chris H. Polman, Paul O'Connor, Andrew D. Goodman, Stephanie A. Jurgensen, Richard A. Rudick, Nancy M. Griffith, Fiona Forrestal, Susan Goelz, Soma Ray, Alfred Sandrock
Publikováno v:
Annals of Neurology. 68:304-310
Objective Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML). Met
Autor:
Paul O'Connor, Chris H. Polman, Richard A. Rudick, Fiona Forrestal, Andrew D. Goodman, Ludwig Kappos, Fred D. Lublin, Lynda M. Cristiano, Kathy Hauswirth, Petra Duda
Publikováno v:
Neurology, 83(1), 78-86. Lippincott Williams and Wilkins
O'Connor, P, Goodman, A, Kappos, L, Lublin, F, Polman, C, Rudick, R A, Hauswirth, K, Cristiano, L M, Forrestal, F & Duda, P 2014, ' Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study ', Neurology, vol. 83, no. 1, pp. 78-86 . https://doi.org/10.1212/WNL.0000000000000541
O'Connor, P, Goodman, A, Kappos, L, Lublin, F, Polman, C, Rudick, R A, Hauswirth, K, Cristiano, L M, Forrestal, F & Duda, P 2014, ' Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study ', Neurology, vol. 83, no. 1, pp. 78-86 . https://doi.org/10.1212/WNL.0000000000000541
Objectives: Report long-term safety and effectiveness of natalizumab over 240 weeks in the prospective, observational, open-label Safety of TYSABRI Re-dosing and Treatment (STRATA) Study. Methods: Patients (N = 1,094) previously enrolled in natalizum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::907fd687b7693b0bdfad02b2912b0e5c
https://research.vumc.nl/en/publications/a300b082-2545-4cf0-a786-470aee7162ce
https://research.vumc.nl/en/publications/a300b082-2545-4cf0-a786-470aee7162ce